Regulations for DX, Pre-Symptomatic Disease Up for JPMA Committee Discussion

Yuji Kashitani, Chairperson, Regulatory Affairs Committee, JPMA The Japan Pharmaceutical Manufacturers Association (JPMA) is to spend the next few years to discuss new regulations and company responses that might be required for digital transformations (DX) and pre-symptomatic diseases, the group’s...read more